Anti-FCN2/ EBP-37/ FCNL functional antibody
Anti-FCN2/ EBP-37/ FCNL functional antibody for cell culture, ELISA & in-vivo assay
Go to FCN2/FCN2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE0211-Ab-1/ GM-Tg-hg-SE0211-Ab-2 | Anti-Human FCN2 monoclonal antibody | Human |
GM-Tg-rg-SE0211-Ab-1/ GM-Tg-rg-SE0211-Ab-2 | Anti-Rat FCN2 monoclonal antibody | Rat |
GM-Tg-mg-SE0211-Ab-1/ GM-Tg-mg-SE0211-Ab-2 | Anti-Mouse FCN2 monoclonal antibody | Mouse |
GM-Tg-cynog-SE0211-Ab-1/ GM-Tg-cynog-SE0211-Ab-2 | Anti-Cynomolgus/ Rhesus macaque FCN2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE0211-Ab-1/ GM-Tg-felg-SE0211-Ab-2 | Anti-Feline FCN2 monoclonal antibody | Feline |
GM-Tg-cang-SE0211-Ab-1/ GM-Tg-cang-SE0211-Ab-2 | Anti-Canine FCN2 monoclonal antibody | Canine |
GM-Tg-bovg-SE0211-Ab-1/ GM-Tg-bovg-SE0211-Ab-2 | Anti-Bovine FCN2 monoclonal antibody | Bovine |
GM-Tg-equg-SE0211-Ab-1/ GM-Tg-equg-SE0211-Ab-2 | Anti-Equine FCN2 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE0211-Ab-1/ GM-Tg-hg-SE0211-Ab-2; GM-Tg-rg-SE0211-Ab-1/ GM-Tg-rg-SE0211-Ab-2; GM-Tg-mg-SE0211-Ab-1/ GM-Tg-mg-SE0211-Ab-2; GM-Tg-cynog-SE0211-Ab-1/ GM-Tg-cynog-SE0211-Ab-2; GM-Tg-felg-SE0211-Ab-1/ GM-Tg-felg-SE0211-Ab-2; GM-Tg-cang-SE0211-Ab-1/ GM-Tg-cang-SE0211-Ab-2; GM-Tg-bovg-SE0211-Ab-1/ GM-Tg-bovg-SE0211-Ab-2; GM-Tg-equg-SE0211-Ab-1/ GM-Tg-equg-SE0211-Ab-2 |
Products Name | Anti-FCN2 monoclonal antibody |
Format | mab |
Target Name | FCN2 |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-FCN2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE0211-Ag-1 | Recombinant multi-species FCN2/ EBP-37/ FCNL protein |
ORF Viral Vector | pGMLP004783 | human FCN2 Lentivirus plasmid |
ORF Viral Vector | vGMLP004783 | human FCN2 Lentivirus particle |
ORF Viral Vector | pGMLPm000560 | mouse Fcnb Lentivirus plasmid |
ORF Viral Vector | vGMLPm000560 | mouse Fcnb Lentivirus particle |
Target information
Target ID | GM-SE0211 |
Target Name | FCN2 |
Gene ID | 2220 |
Gene Symbol and Synonyms | EBP-37,FCN1,FCN2,FCNL,ficolin-2,P35 |
Uniprot Accession | Q15485 |
Uniprot Entry Name | FCN2_HUMAN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000160339 |
Target Classification | N/A |
The target: FCN2, gene name: FCN2, also named as EBP-37, FCNL, P35, ficolin-2. The product of this gene belongs to the ficolin family of proteins. This family is characterized by the presence of a leader peptide, a short N-terminal segment, followed by a collagen-like region, and a C-terminal fibrinogen-like domain. This gene is predominantly expressed in the liver, and has been shown to have carbohydrate binding and opsonic activities. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.